
Annalisa Jenkins
Annalisa Jenkins, MD, is a life sciences thought leader with more than 25 years of biopharmaceutical industry experience. Jenkins served as president and CEO of Dimension Therapeutics, a leading NASDAQ-listed gene therapy company that was acquired by Ultragenyx in November 2017.
Prior leadership roles include head of global research and development at Merck Serono and several senior positions at Bristol Myers-Squibb. Jenkins is a board member and advisor to numerous public and private health and life sciences companies globally. She is a trustee of the British Heart Foundation, Cancer Research Horizons at Cancer Research UK, and a board member at Genomics England. She previously served as a committee member of the Science Board of the US Food and Drug Administration and as chair of The Court of The London School of Hygiene and Tropical Medicine. Jenkins graduated with a degree in medicine from St. Bartholomew’s Hospital at the University of London.